Incretin Atlas › Trials › TRIUMPH-1
TRIUMPH-1
Retatrutide · obesity
Design
- Molecule(s)
- Retatrutide
- Population
- obesity
- Official title
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2023-07 → 2026-04
- Participants
- 2335
- Duration
- 80 weeks
- Registry
- NCT05929066
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| retatrutide 4 mg | obesity | 80 | 584 | −19.0 % vs −2.2 % Δ −16.8 pp | −17.6 % vs −3.9 % Δ −13.7 pp | — | 4.1 vs 4.6 | — | 28.6 vs 14.8 | 10.6 vs 4.8 | 7.7 vs 5.5 | −7.6 vs −1.9 | verified |
| retatrutide 9 mg | obesity | 80 | 584 | −25.9 % vs −2.2 % Δ −23.7 pp | −23.7 % vs −3.9 % Δ −19.8 pp | — | 6.5 vs 4.6 | — | 38.4 vs 14.8 | 22.8 vs 4.8 | 7.7 vs 5.5 | −9.8 vs −1.9 | verified |
| retatrutide 12 mg | obesity | 80 | 584 | −28.3 % vs −2.2 % Δ −26.1 pp | −25.0 % vs −3.9 % Δ −21.1 pp | — | 11.2 vs 4.6 | — | 42.4 vs 14.8 | 25.3 vs 4.8 | 10.5 vs 5.5 | −10.4 vs −1.9 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (21)
- retatrutide 4 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
- retatrutide 4 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
−17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
- retatrutide 4 mg · ae_dc · Table 3
Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
- retatrutide 4 mg · nausea · Table 3
Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
- retatrutide 4 mg · vomiting · Table 3
Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
- retatrutide 4 mg · sae · Table 3
Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
- retatrutide 4 mg · sbp · Table 2 (continued)
Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
- retatrutide 9 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
- retatrutide 9 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
−17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
- retatrutide 9 mg · ae_dc · Table 3
Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
- retatrutide 9 mg · nausea · Table 3
Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
- retatrutide 9 mg · vomiting · Table 3
Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
- retatrutide 9 mg · sae · Table 3
Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
- retatrutide 9 mg · sbp · Table 2 (continued)
Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
- retatrutide 12 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
- retatrutide 12 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
−17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
- retatrutide 12 mg · ae_dc · Table 3
Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
- retatrutide 12 mg · nausea · Table 3
Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
- retatrutide 12 mg · vomiting · Table 3
Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
- retatrutide 12 mg · sae · Table 3
Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
- retatrutide 12 mg · sbp · Table 2 (continued)
Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
Primary sources
- Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
- ClinicalTrials.gov NCT05929066
How to cite this page
Medical Adviser's Group. Incretin Atlas: TRIUMPH-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.